- Home
- SPPL vs SNSE Comparison
SPPL vs SNSE Comparison
Compare SPPL & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPPL
- SNSE
- Stock Information
- Founded
- SPPL 2016
- SNSE 2005
- Country
- SPPL Singapore
- SNSE United States
- Employees
- SPPL N/A
- SNSE N/A
- Industry
- SPPL
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- SPPL
- SNSE Health Care
- Exchange
- SPPL Nasdaq
- SNSE Nasdaq
- Market Cap
- SPPL 9.8M
- SNSE 10.8M
- IPO Year
- SPPL 2023
- SNSE 2021
- Fundamental
- Price
- SPPL $3.50
- SNSE $6.98
- Analyst Decision
- SPPL
- SNSE Strong Buy
- Analyst Count
- SPPL 0
- SNSE 3
- Target Price
- SPPL N/A
- SNSE $86.67
- AVG Volume (30 Days)
- SPPL 43.2K
- SNSE 9.3K
- Earning Date
- SPPL 01-01-0001
- SNSE 08-05-2025
- Dividend Yield
- SPPL N/A
- SNSE N/A
- EPS Growth
- SPPL N/A
- SNSE N/A
- EPS
- SPPL N/A
- SNSE N/A
- Revenue
- SPPL $2,764,846.00
- SNSE N/A
- Revenue This Year
- SPPL N/A
- SNSE N/A
- Revenue Next Year
- SPPL N/A
- SNSE N/A
- P/E Ratio
- SPPL N/A
- SNSE N/A
- Revenue Growth
- SPPL N/A
- SNSE N/A
- 52 Week Low
- SPPL $2.02
- SNSE $5.00
- 52 Week High
- SPPL $16.80
- SNSE $17.40
- Technical
- Relative Strength Index (RSI)
- SPPL 60.28
- SNSE 36.47
- Support Level
- SPPL $3.01
- SNSE $7.62
- Resistance Level
- SPPL $3.45
- SNSE $8.42
- Average True Range (ATR)
- SPPL 0.34
- SNSE 0.61
- MACD
- SPPL 0.03
- SNSE -0.23
- Stochastic Oscillator
- SPPL 56.60
- SNSE 9.13
About SPPL SIMPPLE LTD.
Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software. The majority of its revenue is generated from the Robots segment.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).